All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld Perspectives » What Would Albus Do? And What Should We?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Cancer

What Would Albus Do? And What Should We?

Feb. 13, 2012
By Anette Breindl
No Comments

There’s a story, sometimes used to illustrate the difference between counseling and research psychology, about a man who pulls out one, then a second, then a third drowning person out of a river. When he sees a fourth, he starts walking upstream, prompting a bystander to ask “Aren’t you going to pull that one out, too?” Our hero answers “No, I’m going upstream to figure out what’s pushing all these people in.”

In the Harry Potter books, Hogwarts headmaster Albus Dumbledore reacts the opposite way to a similar conflict as he comes to care for Harry Potter in ways that are hard to square with the responsibility to the larger wizarding world which is also his duty. He speaks to Harry of wanting to “save you more pain than you had already suffered. What did I care if numbers of nameless and faceless people and creatures were slaughtered in the vague future, if in the here and now you were alive, well and happy?”

Clinical trials and their individual patients can face the same tensions. Treating patients according to the best evidence that is available now affects the evidence of the future.

One example is crossover designs, where patients in the control group have the chance to get the experimental treatment.

The scientific problem with this approach is not hard to see. If the control group is also receiving the active agent, and the active agent affects overall survival, then survival time in the control group will be lengthened by the investigational agent, and the difference between the two groups will be less pronounced.

Even where survival effects are strong enough to be visible at interim analyses, crossover effects will affect the final survival benefit. And that’s not just an academic concern. Taking crossover benefits into account, the survival time for Provenge almost doubles. Other trials seem to have missed their endpoints altogether due to crossover effects.

I’m not here to defend sky-high drug prices. As my colleague Mari Serebrov has movingly written about on this blog post, a cure that no one can afford is no cure at all. And I rather suspect that even after you take the high price of drug discovery into account, the profit margins on a number of drugs would raise eyebrows.

But just as we can’t lose sight of the needs of the individual patient of today, we need to remember that unless the numbers add up – unless companies can survive, unless trials are set up to be able to demonstrate benefits of the drugs they test – we can also end up doing a disservice to the patients of tomorrow.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing